Jonathan C DeLong1, Takashi Murakami2, Paul J Yazaki3, Robert M Hoffman4, Michael Bouvet5. 1. Department of Surgery, University of California San Diego, San Diego, California. 2. Department of Surgery, University of California San Diego, San Diego, California; AntiCancer, Inc, San Diego, California; Department of Surgery, Yokohama City University, Yokohama City, Japan. 3. Beckman Research Institute, City of Hope Medical Center, Duarte, California. 4. Department of Surgery, University of California San Diego, San Diego, California; AntiCancer, Inc, San Diego, California. 5. Department of Surgery, University of California San Diego, San Diego, California; Department of Surgery, VA Healthcare System, San Diego, California. Electronic address: mbouvet@ucsd.edu.
Abstract
BACKGROUND: The success of a curative surgery for cancer is dependent on the complete removal of all cancer cells. Tumor visualization by the surgeon can be enhanced through fluorescent-antibody targeting. To further develop such technology, we selected humanized anti-carcinoembryonic antigen (CEA) conjugated to a near-infrared dye to target orthotopically-implanted human colon cancer in nude mice. MATERIALS AND METHODS: The HT-29 human colon cancer cell line was grown in culture and subcutaneously injected in mice. After 3 wk of growth, tumors were resected and cut into 2 mm3 fragments that were sutured to the cecum of five additional nude mice for orthotopic implantation. The tumors were allowed to grow for 4 wk at which point 3 had successful orthotopic tumor growth and were selected for injection of the humanized anti-CEA antibody conjugated to the near-infrared dye IRDye800CW (anti-CEA-IRDye800CW). The antibody-dye conjugate (75 μg) was administered via tail vein injection. Images were obtained with the Pearl Trilogy Small Animal Imaging System with both 700 and 800 nm channels and evaluated using Image Studio. RESULTS: Laparotomy was performed 24 h after labeling the tumors. When imaged through the 800 nm channel, the tumors were observed to be strongly labeled with anti-CEA-IRDye800. At 48 h, laparotomy was repeated which again demonstrated strong labeling of the tumors through the 800 nm channel, but with a lower absolute intensity (in relative units), than at 24 h. CONCLUSIONS: Humanized anti-CEA-IRDye800CW can rapidly and effectively label CEA-expressing human colon cancer in an orthotopic nude mouse model. Given the ability of this technology to target and label tumors with great specificity, the anti-CEA-IRDye800CW is currently being developed for clinical use in fluorescence-guided surgery.
BACKGROUND: The success of a curative surgery for cancer is dependent on the complete removal of all cancer cells. Tumor visualization by the surgeon can be enhanced through fluorescent-antibody targeting. To further develop such technology, we selected humanized anti-carcinoembryonic antigen (CEA) conjugated to a near-infrared dye to target orthotopically-implanted humancolon cancer in nude mice. MATERIALS AND METHODS: The HT-29humancolon cancer cell line was grown in culture and subcutaneously injected in mice. After 3 wk of growth, tumors were resected and cut into 2 mm3 fragments that were sutured to the cecum of five additional nude mice for orthotopic implantation. The tumors were allowed to grow for 4 wk at which point 3 had successful orthotopic tumor growth and were selected for injection of the humanized anti-CEA antibody conjugated to the near-infrared dye IRDye800CW (anti-CEA-IRDye800CW). The antibody-dye conjugate (75 μg) was administered via tail vein injection. Images were obtained with the Pearl Trilogy Small Animal Imaging System with both 700 and 800 nm channels and evaluated using Image Studio. RESULTS: Laparotomy was performed 24 h after labeling the tumors. When imaged through the 800 nm channel, the tumors were observed to be strongly labeled with anti-CEA-IRDye800. At 48 h, laparotomy was repeated which again demonstrated strong labeling of the tumors through the 800 nm channel, but with a lower absolute intensity (in relative units), than at 24 h. CONCLUSIONS: Humanized anti-CEA-IRDye800CW can rapidly and effectively label CEA-expressing humancolon cancer in an orthotopic nude mouse model. Given the ability of this technology to target and label tumors with great specificity, the anti-CEA-IRDye800CW is currently being developed for clinical use in fluorescence-guided surgery.
Authors: Paul J Yazaki; Brian Lee; Divya Channappa; Chia-Wei Cheung; Desiree Crow; Junie Chea; Erasmus Poku; Lin Li; Jan Terje Andersen; Inger Sandlie; Kelly Davis Orcutt; K Dane Wittrup; John E Shively; Andrew Raubitschek; David Colcher Journal: Protein Eng Des Sel Date: 2012-11-21 Impact factor: 1.650
Authors: Ali A Maawy; Yukihiko Hiroshima; Sharmeela Kaushal; George A Luiken; Robert M Hoffman; Michael Bouvet Journal: J Biomed Opt Date: 2013-12 Impact factor: 3.170
Authors: Sharmeela Kaushal; Michele K McElroy; George A Luiken; Mark A Talamini; A R Moossa; Robert M Hoffman; Michael Bouvet Journal: J Gastrointest Surg Date: 2008-07-30 Impact factor: 3.452
Authors: Cristina A Metildi; Sharmeela Kaushal; Minya Pu; Karen A Messer; George A Luiken; Abdool R Moossa; Robert M Hoffman; Michael Bouvet Journal: Ann Surg Oncol Date: 2014-02-06 Impact factor: 5.344
Authors: Hannah M Hollandsworth; Hiroto Nishino; Michael Turner; Siamak Amirfakhri; Filemoni Filemoni; Robert M Hoffman; Paul J Yazaki; Michael Bouvet Journal: In Vivo Date: 2020 Sep-Oct Impact factor: 2.155
Authors: Hannah M Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Robert M Hoffman; Justin Molnar; Paul J Yazaki; Michael Bouvet Journal: J Surg Res Date: 2020-03-24 Impact factor: 2.192
Authors: Hannah M Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Justin Molnar; Robert M Hoffman; Paul Yazaki; Michael Bouvet Journal: PLoS One Date: 2020-06-18 Impact factor: 3.240
Authors: Thinzar M Lwin; Michael A Turner; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Michael Bouvet Journal: Cells Date: 2022-01-12 Impact factor: 6.600
Authors: Michael A Turner; Thinzar M Lwin; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Paul J Yazaki; Michael Bouvet Journal: Biomolecules Date: 2021-12-02